Lv2
106 积分 2021-06-11 加入
First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon
3天前
已完结
Mechanisms and regulation of cholesterol homeostasis
5天前
已完结
New and Emerging Therapies for Dyslipidemia
16天前
已完结
Protecting against fatty liver disease
17天前
已完结
Epigenome editing technologies for discovery and medicine
25天前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Recent Progress in Glucose-Responsive Insulin
1个月前
已完结
Molecular Glue Discovery: Current and Future Approaches
2个月前
已完结
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
2个月前
已完结
Small molecule modulators of PCSK9 – A literature and patent overview
2个月前
已完结
皖公网安备34019202002308
